Previous 10 | Next 10 |
MediciNova reported blasé Q2 2021 earnings on 08/12/2021. MediciNova's core pipeline consists of two candidate therapies being developed in treatment of eleven indications. MediciNova's MS program is a high potential, late stage program which has been in stall mode. Medic...
LA JOLLA, Calif., Aug. 30, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding MediciNova’s ongoing Ph...
Initiated preclinical animal studies for MN-166 as a treatment for chlorine gas-induced induced lung disease under partnership with BARDA Positive Phase 2 results in alcohol use disorder published in Nature Journal reinforce safety and blockbuster potential of MN-166 Pha...
Shares of MediciNova Inc. (NASDAQ:MNOV) traded at a new 52-week low today of $3.68. Approximately 3.3 million shares have changed hands today, as compared to an average 30-day volume of 1.5 million shares. Over the past year, MediciNova Inc. has traded in a range of $3.68 to $13.25 and i...
MediciNova (MNOV) jumps 9.5% premarket after announcing that it has received a Notice of Allowance from the USPTO for a pending patent application which covers MN-166 (ibudilast) for the treatment of ophthalmic disease. Once issued, the patent is expected to expire no earlier t...
LA JOLLA, Calif., July 06, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the ...
LA JOLLA, Calif., June 29, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Yuichi Iwaki, MD, PhD, President and Chief Executive...
LA JOLLA, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it will conduct a mouse study to investigate the efficacy...
Tarsus Pharmaceuticals (NASDAQ: TARS) , Anavex Life Sciences (NASDAQ: AVXL) , and MediciNova (NASDAQ: MNOV) all had recent positive news coming out of phase 2 clinical trials that should whet investors' appetites. Investing in a stock based mainly on a solid phas...
Shares of MediciNova Inc. (NASDAQ:MNOV) traded today at $3.84, breaking its 52-week low. Approximately 3.3 million shares have changed hands today, as compared to an average 30-day volume of 298,000 shares. MediciNova Inc. (NASDAQ:MNOV) has potential upside of 38.3% based on a current pr...
News, Short Squeeze, Breakout and More Instantly...
Company to rededicate efforts toward updating stakeholders on corporate vision, strategy, and ongoing activities LA JOLLA, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market o...
LA JOLLA, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S....
LA JOLLA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s collaborator, Gilbert Youssef, M.D....